OpenAI has introduced a major update to GPT-Rosalind, its life sciences-focused model, by integrating GPT-5.5 agentic capabilities for drug discovery and genomics research.
The upgrade is designed to help researchers perform more advanced scientific workflows, including large-scale biological data analysis, target identification, and genomic research. The move highlights the growing role of AI in accelerating medical innovation, reducing research costs, and shortening the timeline for discovering new treatments.